by Liliana Resende | Jul 8, 2021 | News
Ribavirin is the only available Lassa fever–specific treatment and has been used routinely for over 25 years. However, Ribavirin is not licensed for Lassa fever, its mechanism of action is unclear, it’s expensive and hard to source, and it has well-known...
by Liliana Resende | Mar 24, 2021 | News
Women under 50 and people who experienced severe disease had worse long-term outcomes following hospitalisation with COVID-19. The first long-term follow-up data from the International Severe Acute Respiratory and emerging Infections Consortium (ISARIC) Clinical...
by Liliana Resende | Mar 10, 2021 | News
In the largest study of its kind to date, the UK’s International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC), supported by the UK Coronavirus Immunology Consortium (UK-CIC), has identified new biomarkers of inflammation that both indicate the...
by Liliana Resende | Feb 15, 2021 | News, Uncategorised
The Lancet Infectious Diseases published the GloPID-R and ISARIC Long COVID Forum Working Group’ letter, describing the content and discussions of the Long COVID Forum which took place on 9-10 December 2020. This global public forum, organised by ISARIC, GloPID-R and...
by Liliana Resende | Jan 18, 2021 | News
The spread of COVID-19 in Brazil overwhelmed the health systems in all the country’s regions, particularly in areas where they were already fragile, according to a collaborative effort involving ISGlobal, an institution supported by the ”la Caixa” Foundation, the...
by Liliana Resende | Jan 18, 2021 | News
ISARIC 4C has developed a new tool to predict a person’s risk of being admitted to hospital and dying from COVID-19, the ISARIC 4C Deterioration model. There is an urgent need for reliable models that predict the likely course of COVID-19, to support decisions...
